Literature DB >> 12452304

Comparison of primary angioplasty and conservative treatment on short- and long-term outcome in octogenarian or older patients with acute myocardial infarction.

Hon-Kan Yip1, Chiung-Jen Wu, Hsueh-Wen Chang, Chi-Ling Hang, Chih-Yuan Fang, Yuan-Kai Hsieh, Cheng-Hsu Yang, Chien-Jen Chen, Kuo-Ho Yeh, Sarah Chua, Morgan Fu, Mien-Cheng Chen.   

Abstract

It has long been established that advanced age is not only associated with greater myocardial infarction frequency but also greater mortality and morbidity. The treatment of acute myocardial infarction (AMI) in 80 year old patients remains problematic with conflicting results; in these patients, the risks of conservative treatment are high and the risks and benefits of thrombolytic therapy are still controversial. The purpose of this study was to evaluate whether primary angioplasty can offer an important alternative method to improve short- and long-term outcomes in octogenarian or older patients who experience AMI. Between May 1986 and March 2000, 171 consecutive 80 year old patients hospitalized for AMI were not randomized to be registered and divided into a medical therapy group (group 1: an historical control group, n=11) and a primary angioplasty group (group 2, n=60). In-hospital mortality was markedly increased with advanced Killip scores (Killip 3 or 4) in both groups. Twenty-four hours after admission, group 1 patients had a significantly higher incidence of progression to higher Killip scores than did group 2 patients (P=0.006). The 30-day overall mortality of group 2 patients was significantly lower than in group 1 patients (30.0% vs 54.1%, P=0.003). Patients without cardiogenic shock treated by primary angioplasty had a significantly lower incidence of overall mortality at 30 days than patients without cardiogenic shock treated conservatively [3.1% vs 24.3%, P=0.016 (Killip 1 and 2); 18.2% vs 52.6%, P=0.044 (Killip 3)]. However, the mortality rate of cardiogenic shock was extremely high and did not differ significantly between groups I and 2 (86.1% vs 88.2%, P=0.99). The 3-year cumulative survival rate was significantly higher in group 2 than in group 1 patients (P=0.0009). In conclusion, primary angioplasty is feasible and effective, and can improve short-and long-term mortalities in octogenarian or older patients with AMI but without cardiogenic shock.

Entities:  

Mesh:

Year:  2002        PMID: 12452304     DOI: 10.1536/jhj.43.463

Source DB:  PubMed          Journal:  Jpn Heart J        ISSN: 0021-4868


  4 in total

1.  Timing, setting and incidence of cardiovascular complications in patients with acute myocardial infarction submitted to primary percutaneous coronary intervention.

Authors:  Cristina Giglioli; Massimo Margheri; Serafina Valente; Marco Comeglio; Chiara Lazzeri; Tania Chechi; Corinna Armentano; Salvatore Mario Romano; Massimilano Falai; Gian Franco Gensini
Journal:  Can J Cardiol       Date:  2006-10       Impact factor: 5.223

2.  Application and Comparison of Different Prognostic Scoring Systems in Patients Who Underwent Cardiologist-Managed Percutaneous Cardiopulmonary Support.

Authors:  Shih-Chieh Chien; Wei-Ren Lan; Shu-Hao Wu; Chen-Yen Chien; Yu-Shan Chien; Chi-In Lo; Cheng-Ting Tsai; Chun-Yen Chen
Journal:  Acta Cardiol Sin       Date:  2020-07       Impact factor: 2.672

3.  Clinical outcomes of elderly South-East Asian patients in primary percutaneous coronary intervention for ST-elevation myocardial infarction.

Authors:  Jieli Tong; Wen Wei Xiang; An Shing Ang; Wen Jun Sim; Kien Hong Quah; David Foo; Paul Jau Lueng Ong; Hee Hwa Ho
Journal:  J Geriatr Cardiol       Date:  2016-10       Impact factor: 3.327

4.  Higher neutrophil counts and neutrophil-to-lymphocyte ratio predict prognostic outcomes in patients after non-atrial fibrillation-caused ischemic stroke.

Authors:  Yen-Nan Fang; Meng-Shen Tong; Pei-Hsun Sung; Yung-Lung Chen; Chih-Hung Chen; Nei-Wen Tsai; Chih-Jen Huang; Ya-Ting Chang; Shu-Fang Chen; Wen-Neng Chang; Cheng-Hsien Lu; Hon-Kan Yip
Journal:  Biomed J       Date:  2017-05-30       Impact factor: 4.910

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.